Week Ahead: U.S Cannabis Earnings Expectations For CRON, CURA, IIPR And More

Cannabis investors are facing a harsh 2023 as shares of the largest U.S cannabis companies are off between 70% and 90% from their all-time highs in February 2021. They are also now seeing the fundamentals lagging behind once high-flying expectations.

There are many reasons for this deterioration in fundamentals, such as higher-than-expected borrowing rates and general loss of interest in the sector, making it harder for these money incinerators to raise money. At the same time they are also facing mismatched supply and demand issues, partly due to COVID-19 stimulus checks pulling forward demand, as well as due to the the industry spending significantly on large CapEx projects between 2020 and 2022, much of which came online throughout 2022, creating major supply imbalances.

Though we are nearing the end of the earning season for major industries, the cannabis earning season is just getting underway, with the first batch of U.S cannabis companies reporting this week.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Cronos Group (TSX: CRON)

Cronos, the Canadian cannabis company, is reporting its fourth quarter financial results on Tuesday, February 28th, before the market opens.

  • Revenue: $22.55m
  • Net Income: -$20.52m
  • Earnings Per Share: -$0.06
  • EBITDA: -$19.00m
  • Operating Cash Flow: $1.00m

Innovative Industrial Properties (NYSE: IIPR)

Innovative Industrial Properties, the largest U.S cannabis real estate investment trust, will report its fourth-quarter financial results on Tuesday, February 28th, after the market closes.

  • Revenue: $68.78m
  • Net Income: $36.29m
  • Earnings Per Share: $1.22
  • EBITDA: $58.14m
  • Operating Cash Flow: $61.07m

Green Thumb Industries (CSE: GTII)

Green Thumb will report its fourth-quarter financial results on Tuesday, February 28th, after the market closes.

  • Revenue: $254.84m
  • Net Income: $14.05m
  • Earnings Per Share: $0.06
  • EBITDA: $81.41m
  • Operating Cash Flow: $49.29m
  • Free Cash Flow: $4.06m

Curaleaf Holdings (CSE: CURA)

Curaleaf will report its fourth-quarter financial results on Wednesday, March 1st, after the market closes.

  • Revenue: $354.07m
  • Net Income: -$25.58m
  • Earnings Per Share: -$0.03
  • EBITDA: $85.38m
  • Operating Cash Flow: $4.96m
  • Free Cash Flow: -$39.69m

Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Tungsten Went 6X. I Went to See the Deposit Time Forgot | DD-on-the-GO! – Rackla Metals Inc

The World’s Largest Undeveloped Gold Project Nears a Deal | Rudi Fronk – Seabridge Gold

One of the World’s Biggest Copper Mines Could Reopen Just to Shut Down | First Quantum

Recommended

First Majestic Produces 3.4 Million Ounces of Silver in Q3 2026, Jerritt Canyon Restart Remains on Track

Altamira Gold Drills 134 Metres of 0.5 g/t Gold at Maria Bonita, Hole Ends in Mineralization

Related News

Shopify: Canaccord Raises Price Target To $1,450 Off Back Of Strong Earnings

Shopify (NYSE: SHOP) reported second-quarter financials on July 28th. The company is keeping the US...

Friday, July 30, 2021, 04:32:00 PM

BMO Upgrades AngloGold To Outperform, Raises Price Target To $36

This morning, BMO Capital Markets upgraded AngloGold Ashanti (NYSE: AU) to outperform and upgraded their...

Tuesday, December 8, 2020, 11:34:03 AM

Meta Platforms: Canaccord Anticipates Headwinds To Persist, Cuts Target To $200

On October 26th, Meta Platforms Inc (Nasdaq: META) reported its third-quarter financial results. The company...

Thursday, November 3, 2022, 12:52:00 PM

Dollarama: Canaccord Lifts Target To $72

Dollarama Inc (TSX: DOL) recently reported its fiscal first-quarter financial results for 2023, ending May...

Saturday, June 25, 2022, 05:06:00 PM

Cognetivity: Echelon Raises Price Target To $1.50 After Biogen Approval

Monday was a very big day for companies who are in the business to help...

Wednesday, June 9, 2021, 11:22:00 AM